State Bank of India’s reported participation in global lending syndicates marks a key moment in India’s outbound acquisition financing landscape.
Sun Pharmaceutical Industries is structuring a massive acquisition of Organon & Co valued at about $11.75 billion, one of the largest overseas pharma deals by an Indian company. The transaction is designed to expand Sun’s footprint in women’s health, biosimilars and specialty medicines across more than 140 markets.
The deal is structured through a combination of internal cash and large-scale international borrowing, reflecting how Indian corporates are increasingly tapping global capital markets for expansion.
Deal Financing Structure
The acquisition is heavily leveraged by design. Sun Pharma is expected to deploy $2–2.5 billion from internal cash reserves, while the remaining funding is being arranged through global banks.
Reports indicate committed financing of nearly $9.25–$9.75 billion, including a short-term bridge facility expected to run for 12–18 months, before being refinanced into longer-term debt instruments.
This structure signals two things: scale discipline and reliance on structured global liquidity rather than domestic balance-sheet expansion.
Global Bank Consortium Role
The financing consortium reportedly includes major international lenders such as JPMorgan Chase, Citigroup and Mitsubishi UFJ Financial Group, alongside other participating banks expected to distribute portions of the loan.
The inclusion of SBI in this ecosystem reflects a broader trend where Indian lenders are increasingly aligning with global banking syndicates rather than acting as sole domestic financiers for large cross-border acquisitions.
While SBI’s exact ticket size has not been disclosed in available filings, its participation signals a strategic shift in how Indian public sector banks engage in offshore corporate finance.
Organon Financial Profile
The acquisition target, Organon & Co, brings a significant but complex financial profile. Market estimates place Organon’s annual revenues at around $6.2 billion (CY26 projections), but the company also carries a substantial debt load of about $8.6 billion as of December 2025.
This leverage profile explains the financing complexity. A large portion of the acquisition structure is effectively debt refinancing layered into the deal itself, making lender coordination critical.
Strategic Pharma Expansion
For Sun Pharma, the deal is not just scale-driven but portfolio-driven. The company is pushing deeper into branded specialty drugs, including dermatology, oncology and women’s health segments.
The acquisition is expected to significantly expand its global product access base across more than 70 established medicines, strengthening distribution reach in developed and emerging markets simultaneously.
Industry estimates suggest the combined entity could see meaningful revenue scaling, though integration and debt absorption remain key execution risks.
India’s Outbound Shift
India’s outbound M&A activity has accelerated sharply in recent quarters, with companies increasingly targeting large global assets rather than incremental overseas expansion. The Sun–Organon transaction, if completed, would sit among the most aggressive overseas pharma acquisitions by an Indian firm.
The participation of SBI in global lending structures highlights a deeper structural change: Indian corporates are no longer solely dependent on domestic banking capacity for mega-deals. Instead, they are increasingly integrated into global credit ecosystems alongside Wall Street and European lenders.
This shift also reflects rising confidence in Indian pharmaceutical firms’ global balance sheets, even as such transactions introduce higher leverage and integration complexity.
